IGF1, insulin like growth factor 1, 3479

N. diseases: 1206; N. variants: 36
Disease: Bladder Neoplasm ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.400 Biomarker disease BEFREE Blocking IGF-1/ERβ/Bcl-2 signalling by either an shRNA targeting ERβ or an anti-IGF-1 neutralizing antibody partially reversed the capacity of CAFs to increase BCa chemoresistance. 31076571 2019
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.400 GeneticVariation disease BEFREE This first prospective study indicates no evidence of an association between plasma IGF-I concentrations and bladder cancer risk. 29971779 2018
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.400 AlteredExpression disease BEFREE Our data confirm the differential expression of IGF-I transcripts in bladder cancer, revealing a distinct suppression of IGF-IEc. 29848696 2018
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.400 Biomarker disease BEFREE Thus, miR‑539/IGF‑1R may be a potential therapeutic target for the treatment of bladder cancer. 29393438 2018
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.400 Biomarker disease BEFREE We characterized the expression of components of the IGF pathway - insulin growth factor receptors (INSR, IGF1R, IGF2R), ligands (INS, IGF1, IGF2), and binding proteins (IGFBP1-7, IGF2BP1-3) - in bladder cancer and its correlation with IGF1R activation, and the anti-proliferative efficacy of an IGF1R kinase inhibitor in this setting. 28882129 2017
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.400 Biomarker disease BEFREE miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling. 28123579 2017
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.400 AlteredExpression disease BEFREE Here, we assessed whether microRNA-145 (miR-145) regulates IGF-IR expression in bladder cancer. 24999188 2014
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.400 Biomarker disease BEFREE FAK and its homolog Proline-rich tyrosine kinase 2 (Pyk2) modulate paxillin activation; however, their role in regulating IGF-IR-dependent signaling and motility in bladder cancer has not been established. 22859931 2012
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.400 Biomarker disease BEFREE Thus, the IGF-IR may also serve as a novel biomarker for bladder cancer. 20395438 2010
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.400 Biomarker disease BEFREE These results present further evidence for the role of IGF-1 in bladder cancer progression. 19415693 2009
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.400 Biomarker disease CTD_human To establish a role for insulin-like growth factor-1 (IGF-1) in bladder cancer susceptibility, we tested the effect of p-cresidine, a potent bladder carcinogen, in transgenic (TG) mice with human IGF-1 expression in the bladder driven by the bovine keratin 5 promoter (referred to as BK5.IGF-1 TG mice). 19415693 2009
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.400 Biomarker disease BEFREE Knockdown of IGF-IR by Antisense Oligodeoxynucleotide auguments the sensitivity of bladder cancer cells to mitomycin. 11749868 2001
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.400 Biomarker disease BEFREE These results suggested that blockage of IGF-IR signaling might potentially contribute to the treatment of bladder cancer cells which are insensitive to chemotherapy. 11453542 2001
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.400 AlteredExpression disease BEFREE As a prelude to gene transfer studies to determine if H19 is a bladder tumor oncogene, we also evaluated bladder cell lines for expression of H19, IGF-II, IGF-I and the type I IGF receptor. 8618347 1996